Penny stocks usually live or die on one thing, cash. In a world where growth signals are mixed across Europe, the UK, North America and Asia, and where energy prices, inflation and policy decisions can shift sentiment quickly, having a solid balance sheet matters even more for smaller companies. The Elite Penny Stocks screener focuses on stocks that still trade at penny levels but have the financial strength to keep funding their plans. In this article, you will see 3 of the best stocks from that screener that stand out for further research.

MoneyHero (MNY)

Overview: MoneyHero is a personal finance platform that helps consumers in Singapore, Hong Kong, Taiwan and the Philippines compare and apply for credit cards, loans, mortgages, insurance and wealth products, linking them directly with providers. Through consumer brands like MoneyHero, SingSaver and Seedly, as well as its Creatory B2B platform, it also sells advertising, marketing and insurance brokerage services to financial institutions.

Operations: MoneyHero generates most of its revenue from Hong Kong (about US$31.1 million) and Singapore (about US$30.9 million), with smaller contributions from the Philippines (about US$7.4 million) and Taiwan (about US$4.0 million).

Market Cap: US$52.4 million

MoneyHero provides exposure to Asia’s online finance market at penny stock levels, with a personal finance marketplace that connects 8.8 million members to credit, insurance, wealth and loan products. The business is increasingly focusing on higher margin areas such as insurance and wealth, which currently account for 23% of revenue. The latest results indicate a shift toward smaller losses and a profitable Q4. Analysts have published expectations for future revenue and earnings growth, although the company remains in an early, higher risk phase. Funding relies on external borrowing and the board and management are relatively new, so execution and governance are key issues to monitor as Project Odyssey and new products such as Credit Hero Club scale up.

MoneyHero’s pivot toward higher margin insurance and wealth revenue could be masking a bigger shift in the business model. See how the analyst forecasts for MoneyHero lines up with its new strategy and what might still be missing.

Niagen Bioscience (NAGE)

Overview: Niagen Bioscience develops healthy aging products built around nicotinamide riboside, a precursor to NAD+ that is used in dietary supplements, functional ingredients and emerging pharmaceutical applications, and sells them through its own TRU NIAGEN platform, major online marketplaces, specialty retailers and healthcare practitioners.

Operations: Niagen Bioscience generates most of its revenue from consumer products at about US$98.6 million, with ingredients contributing about US$29.1 million and analytical standards and services about US$2.7 million.

Market Cap: US$272.2 million

Niagen Bioscience provides exposure to the growing interest in healthy aging, with NAD+ focused supplements and pharmaceutical grade Niagen products, and a business mix that leans heavily on direct to consumer e commerce. Earnings are currently profitable, with net margins around 14% and return on equity at 22.6%. At the same time, the stock trades at a P/E below peers and below some published fair value estimates. On the other hand, the company faces intense competition, regulatory risk around NAD boosters and injectables, heavy reliance on external funding and rising marketing spend, while management pay is reported to be well above sector norms and one off gains have influenced recent results.

Profitable earnings, a P/E below peers and heavy marketing spend make Niagen Bioscience feel like a story that has not fully priced in its next chapter. Start with the analysis report for Niagen Bioscience and see what could change that narrative.

Sprinklr (CXM)

Overview: Sprinklr provides cloud software that helps large companies manage customer interactions across social media, messaging, voice and traditional channels, using AI to monitor brand sentiment, automate service and run marketing campaigns from a single platform. It combines tools for customer service, social engagement, consumer insights and marketing into one system, supported by consulting, training and managed services.

Operations: Sprinklr generates about US$871.2 million in revenue from software and programming, with around US$436.4 million from the United States and the rest mainly from EMEA at about US$314.7 million.

Market Cap: US$1.2b

Sprinklr sits at the intersection of AI, customer data and marketing budgets, with new products like LLM Insights and the ViralMoment acquisition aimed at helping brands understand how they appear in AI generated answers and social video. At the same time, management is running a large buyback program and focusing on higher renewal rates, which can concentrate value for remaining shareholders if execution stays on track. The catch is that margins have tightened, revenue growth is forecast below the broader US market and customer concentration, higher AI infrastructure costs and strong competitors all limit room for error. For investors, the key issue is whether Sprinklr’s AI initiatives and product updates sufficiently support the current P/E and analyst expectations for future earnings growth.

Sprinklr’s AI story may be only half written, with LLM Insights and social video analytics reshaping how brands appear in customer conversations. Compare that product shift with the analyst forecasts for Sprinklr and see what the market might be missing

The three elite penny stocks in this article are only the starting point, with the full Elite Penny Stocks screener surfacing 21 more companies that share the same cash focused, balance sheet strength and multi bagger potential themes. Use Simply Wall St to identify, filter and analyze the exact catalysts and narratives that matter most to you so you can focus on the ideas from that list that align most closely with your own investment views.

Take Control of Your Investment Journey

If Niagen Bioscience or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives For Your Watchlist?

New breakouts, fresh momentum and under the radar ideas rarely stay quiet for long. Consider researching them before they become crowded opportunities.

• Spot steady compounders by scanning resilient balance sheets and low risk profiles with the curated 67 resilient stocks with low risk scores before they are widely noticed by investors.
• Explore strengthening income trends by checking companies in the curated 7 dividend fortresses while yields are elevated and prices may not fully reflect their cash return profile.
• Evaluate real business traction by reviewing profitable companies inside the focused 62 profitable AI stocks that aren't just burning cash while expectations adjust to their cash generating characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.